Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928583 | 0.89 | MEN1 (0.50) | MEN1KMT2AMAOACES1KDM4E | |
| SCHEMBL12836956 | 0.80 | MEN1 (0.43) | MEN1KMT2ACES1KDM4EALDH1A1 | |
| SCHEMBL16065516 | 0.80 | MEN1 (0.43) | MEN1KMT2AMAOA | |
| SCHEMBL18868448 | 0.78 | MEN1 (0.35) | MEN1KMT2ACES1 | |
| SCHEMBL12057393 | 0.76 | MEN1 (0.61) | MEN1KMT2AMAOACES1KDM4E | |
| SCHEMBL24924048 | 0.75 | MEN1 (0.42) | MEN1KMT2AMAOAKDM4EALDH1A1 | |
| SCHEMBL21755083 | 0.73 | MEN1 (0.50) | MEN1KMT2AMAOACES1BCL2L1 | |
| SCHEMBL1524545 | 0.73 | MEN1 (0.38) | MEN1KMT2AMAOA | |
| SCHEMBL29488431 | 0.73 | MEN1 (0.38) | MEN1KMT2AMAOA | |
| SCHEMBL12793222 | 0.73 | MEN1 (0.38) | MEN1KMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776179-B2 | Production of fatty olefin derivatives via olefin metathesis | PROVIVI, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170137365-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | PROVIVI, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20140330018-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137365-A1 | PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS | SREBF1, F2, SREBF2 | MEN1 348/4885KMT2A 4144/4885MAOA 1786/4885 |
| US-20140330018-A1 | METATHESIS CATALYSTS AND METHODS THEREOF | TERT, CYP19A1, MPO | MEN1 14/4885KMT2A 1441/4885MAOA 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.